Jane Street’s Cidara Therapeutics CDTX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q4 | – | Sell |
-14,604
| Closed | -$2.36M | – | 11224 |
|
|
2025
Q3 | $1.4M | Buy |
+14,604
| New | +$932K | ﹤0.01% | 5612 |
|
|
2025
Q2 | – | Sell |
-27,849
| Closed | -$669K | – | 9728 |
|
|
2025
Q1 | $600K | Buy |
27,849
+15,135
| +119% | +$336K | ﹤0.01% | 6527 |
|
|
2024
Q4 | $342K | Buy |
+12,714
| New | +$207K | ﹤0.01% | 7522 |
|
|
2024
Q2 | – | Sell |
-2,287
| Closed | -$42.1K | – | 9426 |
|
|
2024
Q1 | $42.1K | Buy |
2,287
+1,599
| +232% | +$23K | ﹤0.01% | 8785 |
|
|
2023
Q4 | $10.9K | Buy |
+688
| New | +$11.1K | ﹤0.01% | 8960 |
|
|
2023
Q2 | – | Sell |
-15,326
| Closed | -$389K | – | 8737 |
|
|
2023
Q1 | $389K | Buy |
15,326
+12,202
| +391% | +$346K | ﹤0.01% | 6758 |
|
|
2022
Q4 | $47.3K | Buy |
+3,124
| New | +$37.3K | ﹤0.01% | 8386 |
|
|
2022
Q3 | – | Sell |
-2,031
| Closed | -$20K | – | 9750 |
|
|
2022
Q2 | $20K | Buy |
+2,031
| New | +$25.1K | ﹤0.01% | 9156 |
|
|
2020
Q4 | – | Sell |
-1,510
| Closed | -$86K | – | 7514 |
|
|
2020
Q3 | $86K | Sell |
1,510
-2,281
| -60% | -$161K | ﹤0.01% | 6790 |
|
|
2020
Q2 | $280K | Buy |
3,791
+2,184
| +136% | +$142K | ﹤0.01% | 5934 |
|
|
2020
Q1 | $80K | Buy |
+1,607
| New | +$96.3K | ﹤0.01% | 4999 |
|
Jane Street's CDTX Position: Q4 2025 in Review
Jane Street sold out of Cidara Therapeutics (CDTX) in Q4 2025, closing a stake of 14,604 shares — an estimated $2.36M sold.
Jane Street first reported a position in CDTX in Q1 2020 and held it in 11 quarters. The position peaked at $1.4M in Q3 2025. 255 funds tracked by Wall St. Rank hold CDTX as of Q4 2025.
- Jane Street reported no remaining Cidara Therapeutics position as of Q4 2025 after selling out during the quarter.
- Jane Street sold 14,604 Cidara Therapeutics shares in Q4 2025, an estimated $2.36M.
- Jane Street first reported a position in Cidara Therapeutics in Q1 2020 and held it in 11 quarters.
- Jane Street's Cidara Therapeutics position peaked at $1.4M in Q3 2025.
- 255 funds tracked by Wall St. Rank held Cidara Therapeutics as of Q4 2025.
Based on Jane Street's 13F filing for Q4 2025, filed 12 Feb 2026.